REXULTI (Lundbeck Australia Pty Ltd)
Product name
REXULTI
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
198 (255 working days)
Active ingredients
brexpiprazole
Registration type
EOI
Indication
Treatment of agitation associated with Alzheimer’s dementia (AAD), in patients who are unresponsive to non-pharmacological interventions.